Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call and Q&A reflect a positive outlook, with strong product adoption, strategic cost optimization, and promising guidance for Q4. Despite some headwinds, the company anticipates a strong Q4, supported by effective marketing strategies and expected seasonal demand. The positive sentiment is further bolstered by the focus on expanding training for Evolysse, strategic bundling with Jeuveau, and the potential for long-term revenue growth. However, the lack of specific guidance on tariffs and sales splits introduces some uncertainty, warranting a cautious but optimistic rating.
Key Financial Performance
Global net revenue for Q3 2025 $69 million, a 13% increase over Q3 2024. The growth was driven by the introduction of Evolysse and growth in global Jeuveau.
Global Jeuveau revenue for Q3 2025 $63.2 million. Growth was supported by record consumer demand through the Evolus Rewards program and positive unit growth in the U.S. and internationally.
Evolysse revenue for Q3 2025 $5.7 million. This marked the strongest HA filler debut in over a decade, with sequential demand growth after initial stocking by accounts in the launch quarter.
Reported gross margin for Q3 2025 66.5%. Adjusted gross margin was 67.6%, excluding the amortization of intangibles.
GAAP operating expenses for Q3 2025 $57.3 million, up from $55.5 million in Q2 2025. The increase was partly due to the absence of a $3.9 million reduction related to the revaluation of the contingent royalty obligation in Q2.
Non-GAAP operating expenses for Q3 2025 $49.7 million, down from $54 million in Q2 2025. This reduction reflects strategic cost structure optimization and excludes restructuring charges and other adjustments.
Non-GAAP operating loss for Q3 2025 $3.1 million, compared to $6.7 million in Q3 2024. The improvement was due to operating expense reduction and timing of a major customer event.
Cash balance at the end of Q3 2025 $43.5 million, down from $61.7 million at the end of Q2 2025. The decrease was primarily due to pulling forward inventory purchases ahead of potential tariffs on pharmaceuticals.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Evolysse launch: More than 4,000 customers have completed hands-on training, with the majority purchasing Evolysse. Accounts trained twice showed a 100% increase in purchasing volume. Evolysse generated $5.7 million in Q3 revenue and $15.5 million since launch, marking the strongest HA filler debut in over a decade.
Evolysse Sculpt: PMA submitted to the FDA for advanced injectable HA sculpt for mid-face volume restoration. Approval anticipated in the second half of 2026. Clinical trials showed statistical superiority over Restylane Lyft with a threefold difference in efficacy at 24 months.
International market expansion: Entered two new markets in 2025. Mature markets like the U.K. are growing at high rates, with market share mirroring U.S. uptake.
U.S. market performance: Jeuveau outperformed the U.S. aesthetic market, growing unit volume year-to-date despite market challenges. Strengthened 14% share of the U.S. market.
Consumer loyalty program: Evolus Rewards program grew to 1.3 million members, up 34% year-on-year, with 70% returning customers. Total redemptions grew 34% compared to the prior year quarter.
Expense management: Rebased expenses, reflected in Q3 results, positioning the company for sustainable profitability by 2026.
Portfolio bundling strategy: Introduced Evolus portfolio bundle in Q4 2025 to reward practices growing across both Jeuveau and Evolysse, aiming to drive market share gains.
Pipeline development: Broader launch of a steam in Europe planned for the first half of 2026. Lyft HA injectable trial ongoing, with approval and launch expected in 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Consumer Spending Challenges: The U.S. aesthetic market is facing near-term challenges related to consumer spending, which could impact demand for injectables and overall revenue growth.
Tariff Uncertainty: Potential tariffs on pharmaceuticals, including Jeuveau, and a 15% tariff on Evolysse under the EU trade agreement could increase costs and impact financial performance.
Regulatory Approval Risks: The FDA approval process for Evolysse Sculpt and other products carries inherent risks, including potential delays or non-approval, which could affect product launch timelines and revenue projections.
Inventory Management: The company has pulled forward inventory purchases to mitigate potential tariff impacts, which could strain cash flow and working capital.
Market Competition: Competitive pressures in the aesthetics market, including bundled offerings from competitors, could challenge Evolus' market share and pricing strategies.
Economic Uncertainty: Broader economic uncertainties could affect consumer behavior and spending on aesthetic treatments, impacting revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Profitability Timeline: Evolus aims to achieve profitability in the fourth quarter of 2025 and sustainable annual profitability beginning in 2026.
Market Demand and Trends: The U.S. aesthetic market is showing early signs of stabilization, with demand for injectables expected to improve sequentially. Jeuveau is poised to regain momentum as the overall toxin category returns to growth.
Revenue Projections: Evolus reiterates its 2025 revenue guidance of $295 million to $305 million, representing 11% to 15% growth over 2024 results. Evolysse is expected to contribute 10% to 12% of total revenue for the full year 2025.
Product Launches and Approvals: Evolysse Sculpt, an advanced injectable HA sculpt for mid-face volume restoration, is anticipated to receive FDA approval in the second half of 2026. A broader launch of a steam in Europe is planned for the first half of 2026. The Lyft HA injectable trial is ongoing, with approval and launch expected in 2027.
Portfolio Bundling Strategy: Evolus has introduced its first portfolio bundle to reward practices that grow across both Jeuveau and Evolysse, aiming to drive market share gains and compete against competitive bundles.
Tariff Impact Mitigation: Evolus is proactively addressing potential tariff impacts on pharmaceuticals, including Jeuveau, and has sufficient inventory to avoid near-term disruptions. Evolysse is subject to a 15% tariff under a new trade agreement with the EU, which has been incorporated into financial outlooks.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What factors are influencing the performance of Evolysse, including headwinds, seasonality, and market sentiment?
A:David Moatazedi explained that the performance of Evolysse is influenced by several factors, including the macro environment, seasonality, and market sentiment. He noted that the HA market is down double digits due to macroeconomic challenges and that Q3 is seasonally low for injectables. However, Q4 is expected to be the strongest quarter due to seasonality and accumulated learnings from the first 6 months of the launch.
Q:What is the conversion rate from training to adoption for Evolysse, and how does training impact adoption?
A:David Moatazedi highlighted that the second training session is critical for converting physicians from trialing to adopting Evolysse. Clinics that undergo a second training show a significant inflection point in adoption. The company has focused on scheduling more second training sessions in Q4 to drive adoption.
Q:What are the usage trends between Evolysse Smooth and Form, and how are they being used across the consumer base?
A:David Moatazedi and Rui Avelar explained that Smooth is a softer gel used for superficial applications, while Form provides more structure and is used for deeper applications. Both products are versatile and can be layered for different effects. Clinicians choose between the two based on patient attributes and treatment goals.
Q:What is the status of the advertising campaign for Evolysse, and what channels are being used?
A:The advertising campaign for Evolysse focuses on co-branded media, including streaming TV spots, billboards, and digital media. Over 1,400 accounts have participated in the co-branded media benefits, which are tied to purchasing criteria. The campaign aims to personalize marketing at scale.
Q:Why did the company avoid bundling Evolysse and Jeuveau initially, and what is the rationale for introducing a bundle now?
A:The company initially avoided bundling to allow customers to learn and gain comfort with Evolysse independently. They introduced consumer loyalty in the second quarter and are now testing a portfolio bundle in Q4. The bundle is seen as a long-term strategy to unlock synergies and alleviate purchasing pressures for clinics.
Q:What actions contributed to the sequential growth of Jeuveau in Q3 despite seasonality, and what is expected in Q4?
A:David Moatazedi mentioned consistent promotional efforts, consumer loyalty programs, and partnerships like the Allure magazine gift with purchase. The annual 11th-day promotion in Q4 is expected to drive higher purchase volumes, making Q4 the busiest season.
Q:What is the split between U.S. and ex-U.S. sales for Jeuveau, and how is the company performing in the market?
A:The company does not provide segment reporting for U.S. and ex-U.S. sales but noted that both markets are growing positively in terms of units. Jeuveau has outpaced the market, which has seen a slight decline, and consumer rewards data shows a 30% year-on-year increase in redemptions.
Q:What are the potential synergies from bundling Jeuveau and Evolysse, and how does the company view this strategy?
A:The portfolio bundle is seen as a long-term strategy to unlock synergies and expand market share. It aims to alleviate purchasing pressures for clinics and is expected to gain more traction with the approval of additional products like Sculpt.
Q:What impact did the Q3 customer event have on operational expenses and Q4 sales?
A:The customer summit was moved from Q3 to Q4, but this did not impact promotional cadence or revenue. The 11th-day promotion, which began in late October, is expected to be a tailwind for Q4 sales.
Q:What are the company's tariff mitigation strategies, and how are they preparing for potential changes?
A:The company is closely monitoring the situation and has pulled forward inventory to allow time for planning. They are working with their partner, Daewoong, to explore options and are open to various scenarios, including potential U.S. manufacturing.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the split between U.S. and ex-U.S. sales for Jeuveau, citing a lack of segment reporting. Additionally, they did not elaborate on the exact tariff mitigation strategies, stating that the situation is still unclear and under scenario planning.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA
Lyft patient
PMA
Sculpt HA
Tatjana
aesthetic portfolio
amortization restructuring
approval
brand launch
bundle
change volume
cheek
customer event
date
demand
difference
endpoint
event group
hand training
improvement scale
ml
patient responder
point change
portfolio brand
profitability portfolio
record consumer
responder patient
restructuring charge
scale patient
submission
tariff
timing customer
trade agreement
volume deficit
website
EOLS Transcript
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary and Q&A reveal several positive indicators, such as strong international growth, effective bundling strategies, and stable market sentiment despite competition. The company maintains healthy margins and anticipates FDA approval for new products. While some responses lacked specificity, the overall sentiment is optimistic, with guidance aligning with consensus estimates and expected growth in key markets. These factors suggest a likely positive stock price movement over the next two weeks.
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Positive3-4
Evolus reported strong financial performance with a 25% YoY revenue increase and improved gross margins. Net income turned positive, reflecting effective cost management. Despite no mention of dividends or buybacks, the solid growth figures and profitability improvements are positive indicators. The absence of negative Q&A feedback further supports a positive sentiment. However, lack of market cap data limits precise prediction.
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Positive11-8
The earnings call and Q&A reflect a positive outlook, with strong product adoption, strategic cost optimization, and promising guidance for Q4. Despite some headwinds, the company anticipates a strong Q4, supported by effective marketing strategies and expected seasonal demand. The positive sentiment is further bolstered by the focus on expanding training for Evolysse, strategic bundling with Jeuveau, and the potential for long-term revenue growth. However, the lack of specific guidance on tariffs and sales splits introduces some uncertainty, warranting a cautious but optimistic rating.
Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary indicates mixed signals: strong market share growth and product launches are positive, but macroeconomic factors and reduced consumer demand are concerning. The Q&A reveals uncertainties, such as the impact of promotions and consumer sentiment. Despite positive long-term targets and a strong product launch, the immediate outlook is tempered by economic challenges and cautious guidance adjustments. Without a clear market cap, it's challenging to predict a strong movement, hence a neutral rating is appropriate.
EOLS Slides
EOLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
